E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/15/2005 in the Prospect News Biotech Daily.

S&P changes Guidant watch to developing

Standard & Poor's said it revised the CreditWatch implications on its ratings for Guidant Corp. to positive from developing. Ratings affected include the A- long-term corporate credit rating, A-2 short-term corporate credit rating, A- senior unsecured debt rating and A-2 commercial paper rating.

This action reflects Johnson & Johnson's announcement that it has agreed to acquire Guidant for $21.5 billion in cash and stock under a revised agreement and S&P's expectation that the merger will likely be consummated.

Johnson & Johnson had previously agreed to acquire Guidant for $25.4 billion in late 2004, but the close of the transaction was delayed due to a subsequent recall of Guidant's pacemakers and implantable defibrillators.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.